Stocks · News reference
Filed: 2026-08-04 AccNo: 0001193125-26-331488 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.
Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
Jefferies analyst Jack Slevin downgrades Pediatrix Medical Group (NYSE:MD) from Buy to Hold and raises the price target from $27 to $28.
UBS analyst A.J. Rice maintains Pediatrix Medical Group (NYSE:MD) with a Neutral and raises the price target from $25 to $28.